Albireo Pharma presented data on Bylvay at the AASLD The Liver Meeting

Albireo Pharma presented new data at the American Association for the Study of Liver Diseases, AASLD, The Liver Meeting 2022 in Washington, D.C. Across three oral presentations, including two late-breakers, and six posters, the Company provided evidence of early, rapid, and sustained efficacy with Bylvay treatment in patients with progressive familial intrahepatic cholestasis and Alagille syndrome. Two key oral presentations on the PEDFIC trials provided evidence of the disease modifying effects of Bylvay in patients with PFIC. The first underscored that a decrease in serum bile acids was strongly associated with native liver survival for up to three years in PFIC patients treated with Bylvay. A second late-breaking oral presentation showed that Bylvay restored bile acid secretion in PFIC patients with bile salt export pump deficiency. The late-breaking abstract was selected by AASLD for inclusion as a key presentation in "The Best of The Liver Meeting" in the Pediatric Hepatology category. "We are pleased to share long term data in PFIC, providing evidence that Bylvay could modify the course of disease, preserving patients’ native liver and improving families’ quality of life by alleviating disease burden," said Jan Mattsson, Ph.D., Chief Scientific Officer and Head of R&D at Albireo. "Furthermore, showing early, rapid, and consistent improvements in pruritus and bile acid levels in patients with Alagille syndrome, through the ASSERT body of evidence, makes for a big year at this year’s AASLD congress. PFIC and Alagille syndrome are devastating childhood diseases and our goal at Albireo has always been to relieve the suffering of these young patients and their families."